

Stefania Chiappini

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5654994/publications.pdf>

Version: 2024-02-01

41
papers

1,304
citations

361045

20
h-index

377514

34
g-index

45
all docs

45
docs citations

45
times ranked

1384
citing authors

#	ARTICLE	IF	CITATIONS
1	Are finasteride-related penile curvature/Peyronie's disease Adverse Event Reports worthy of further clinical investigation? Disproportionality analysis based on both the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) pharmacovigilance databases. <i>International Journal of Impotence Research</i> , 2023, 35, 465-471.	1.0	5
2	Knowledge and Use of Over-the-counter Drugs in Italy: An Exploratory Survey-based Study in the General Population. <i>Current Neuropharmacology</i> , 2023, 21, 133-141.	1.4	3
3	Misuse of Anticholinergic Medications: A Systematic Review. <i>Biomedicines</i> , 2022, 10, 355.	1.4	10
4	A Focus on Abuse/Misuse and Withdrawal Issues with Selective Serotonin Reuptake Inhibitors (SSRIs): Analysis of Both the European EMA and the US FAERS Pharmacovigilance Databases. <i>Pharmaceuticals</i> , 2022, 15, 565.	1.7	9
5	Pharmacovigilance Signals of the Opioid Epidemic over 10 Years: Data Mining Methods in the Analysis of Pharmacovigilance Datasets Collecting Adverse Drug Reactions (ADRs) Reported to EudraVigilance (EV) and the FDA Adverse Event Reporting System (FAERS). <i>Pharmaceuticals</i> , 2022, 15, 675.	1.7	10
6	Atypical Antipsychotic Drugs in Dual Disorders: Current Evidence for Clinical Practice. <i>Current Pharmaceutical Design</i> , 2022, 28, 2241-2259.	0.9	10
7	Is medicinal ketamine associated with urinary dysfunction issues? Assessment of both the European Medicines Agency (<sc>EMA</sc>) and the <sc>UK</sc> Yellow Card Scheme pharmacovigilance database-related reports. LUTS: Lower Urinary Tract Symptoms, 2021, 13, 230-237.	0.6	7
8	Beyond the "purple drank": Study of promethazine abuse according to the European Medicines Agency adverse drug reaction reports. <i>Journal of Psychopharmacology</i> , 2021, 35, 681-692.	2.0	21
9	Opioid painkiller dependence in a sample of elderly medical inpatients. <i>Psychogeriatrics</i> , 2021, 21, 265-271.	0.6	7
10	Editorial: Prescribing Psychotropics: Misuse, Abuse, Dependence, Withdrawal and Addiction. <i>Frontiers in Psychiatry</i> , 2021, 12, 688434.	1.3	3
11	The e-psychonaut drugs' psychopharmacology. <i>Current Opinion in Pharmacology</i> , 2021, 57, 165-174.	1.7	14
12	Focus on Over-the-Counter Drugs' Misuse: A Systematic Review on Antihistamines, Cough Medicines, and Decongestants. <i>Frontiers in Psychiatry</i> , 2021, 12, 657397.	1.3	40
13	"Z-trip"? A Comprehensive Overview and a Case-series of Zolpidem Misuse. <i>Clinical Psychopharmacology and Neuroscience</i> , 2021, 19, 367-387.	0.9	10
14	New psychoactive substances (NPS) and serotonin syndrome onset: A systematic review. <i>Experimental Neurology</i> , 2021, 339, 113638.	2.0	29
15	New Psychoactive Substances and Suicidality: A Systematic Review of the Current Literature. <i>Medicina (Lithuania)</i> , 2021, 57, 580.	0.8	16
16	Therapeutic Potentials of Ketamine and Esketamine in Obsessive-Compulsive Disorder (OCD), Substance Use Disorders (SUD) and Eating Disorders (ED): A Review of the Current Literature. <i>Brain Sciences</i> , 2021, 11, 856.	1.1	42
17	Club Drugs and Psychiatric Sequelae: An Issue of Vulnerability and Previous Psychiatric History. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 6944.	1.2	8
18	Duration of Untreated Disorder and Cannabis Use: An Observational Study on a Cohort of Young Italian Patients Experiencing Psychotic Experiences and Dissociative Symptoms. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 12632.	1.2	16

#	ARTICLE	IF	CITATIONS
19	What about "Pharming"? Issues Regarding the Misuse of Prescription and Over-the-Counter Drugs. <i>Brain Sciences</i> , 2020, 10, 736.	1.1	36
20	COVID-19: The Hidden Impact on Mental Health and Drug Addiction. <i>Frontiers in Psychiatry</i> , 2020, 11, 767.	1.3	101
21	How does ayahuasca work from a psychiatric perspective? Pros and cons of the entheogenic therapy. <i>Human Psychopharmacology</i> , 2020, 35, e2728.	0.7	11
22	Focus on Clozapine Withdrawal- and Misuse-Related Cases as Reported to the European Medicines Agency (EMA) Pharmacovigilance Database. <i>Brain Sciences</i> , 2020, 10, 105.	1.1	20
23	Substance-Use Disorders and Violence. <i>Comprehensive Approach To Psychiatry</i> , 2020, , 95-114.	0.7	6
24	"New/Designer Benzodiazepines": An Analysis of the Literature and Psychonauts' Trip Reports. <i>Current Neuropharmacology</i> , 2020, 18, 809-837.	1.4	51
25	Cannabidiol (CBD) use in psychiatric disorders: A systematic review. <i>NeuroToxicology</i> , 2019, 74, 282-298.	1.4	107
26	Use of Medicinal Cannabis and Synthetic Cannabinoids in Post-Traumatic Stress Disorder (PTSD): A Systematic Review. <i>Medicina (Lithuania)</i> , 2019, 55, 525.	0.8	80
27	The use of new psychoactive substances (NPS) in young people and their role in mental health care: a systematic review. <i>Expert Review of Neurotherapeutics</i> , 2019, 19, 1253-1264.	1.4	16
28	New Psychoactive Substances (NPS), Psychedelic Experiences and Dissociation: Clinical and Clinical Pharmacological Issues. <i>Current Addiction Reports</i> , 2019, 6, 140-152.	1.6	7
29	Pregabalin: A range of misuse-related unanswered questions. <i>CNS Neuroscience and Therapeutics</i> , 2019, 25, 659-660.	1.9	24
30	An Insight into Z-Drug Abuse and Dependence: An Examination of Reports to the European Medicines Agency Database of Suspected Adverse Drug Reactions. <i>International Journal of Neuropsychopharmacology</i> , 2019, 22, 270-277.	1.0	105
31	Assessing the 2004-2018 Fentanyl Misusing Issues Reported to an International Range of Adverse Reporting Systems. <i>Frontiers in Pharmacology</i> , 2019, 10, 46.	1.6	58
32	The Bridge Between Classical and "Synthetic"/Chemical Psychoses: Towards a Clinical, Psychopathological, and Therapeutic Perspective. <i>Frontiers in Psychiatry</i> , 2019, 10, 851.	1.3	24
33	"2-Agonists as Misusing Drugs? Assessment of both Clenbuterol- and Salbutamol-related European Medicines Agency Pharmacovigilance Database Reports. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2018, 123, 182-187.	1.2	26
34	Is There a Potential of Misuse for Quetiapine?. <i>Journal of Clinical Psychopharmacology</i> , 2018, 38, 72-79.	0.7	32
35	Is there such a thing as a 'loper' dope? Analysis of loperamide-related European Medicines Agency (EMA) pharmacovigilance database reports. <i>PLoS ONE</i> , 2018, 13, e0204443.	1.1	30
36	Is There a Potential of Misuse for Venlafaxine and Bupropion?. <i>Frontiers in Pharmacology</i> , 2018, 9, 239.	1.6	27

#	ARTICLE	IF	CITATIONS
37	Abuse of Prescription Drugs in the Context of Novel Psychoactive Substances (NPS): A Systematic Review. <i>Brain Sciences</i> , 2018, 8, 73.	1.1	56
38	Compulsiveness dimension in a case of pathological gambling. <i>European Psychiatry</i> , 2016, 33, S294-S294.	0.1	0
39	A Decade of Gabapentinoid Misuse: An Analysis of the European Medicines Agency's "Suspected Adverse Drug Reactions" Database. <i>CNS Drugs</i> , 2016, 30, 647-654.	2.7	130
40	Methoxetamine-related deaths in the UK: an overview. <i>Human Psychopharmacology</i> , 2015, 30, 244-248.	0.7	38
41	Deaths of individuals aged 16-24 years in the UK after using mephedrone. <i>Human Psychopharmacology</i> , 2015, 30, 225-232.	0.7	50